Landos Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Landos Biopharma

09/08/2023 14:32

* Landos Biopharma Inc  LABP.OQ  reported a quarterly
adjusted
loss of 63 cents​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of $1.10 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Landos Biopharma Inc's reported EPS for the quarter was a
loss
of 63 cents​.
    * The mean earnings estimate of analysts had fallen by
about 4.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Landos Biopharma Inc shares had fallen by 4.9% this
quarter and
lost 20.0% so far this year.
    * The company reported a quarterly loss of $3.92 million.
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $10.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -1.10          -0.63          Beat
 Mar. 31 2023      -0.95          -0.90          Beat
 Dec. 31 2022      -1.90          -1.30          Beat
 Sep. 30 2022      -2.83          -2.00          Beat